Composition, form of production and packaging
The solution for intravenous administration is clear, colorless or slightly colored.
1 ml
Inosine 20 mg
[PRING] hexamethylenetetramine 2 mg, sodium hydroxide solution 1 M to pH 7.8-8.6, water q / and up to 1 ml.
5 ml - ampoules (10) - packs of cardboard.
5 ml - ampoules (10) - cardboard boxes.
10 ml - ampoules (10) - packs of cardboard.
10 ml - ampoules (10) - cardboard boxes.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2011.
PHARMACHOLOGIC EFFECT
Riboxin - a derivative (nucleoside) of purine - a precursor. adenosine triphosphate (ATP). Refers to a group of drugs that stimulate metabolic processes.
Has antihypoxic and antiarrhythmic effect. Increases the energy balance of the myocardium; improves coronary circulation, prevents consequences intraoperative kidney ischemia. It takes a direct part in the exchange of glucose and promotes the activation of metabolism under conditions of hypoxia and in the absence of ATP.Activates the metabolism of pyruvic acid necessary to ensure the normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase.Stimulates the synthesis of nucleotides, enhances the activity of certain enzymes of the Krebs cycle. Penetrating into cells, has a positive effect on metabolic processes in the myocardium, increases the strength of the heart contractions and contributes to a more complete relaxation of the myocardium in diastole, as a result of which the shock volume increases. The mechanism of antiarrhythmic action is not fully understood. Reduces platelet aggregation, activates the regeneration of tissues (especially the myocardium and the mucous membrane of the gastrointestinal tract).
PHARMACOKINETICS
Metabolised in the liver with the formation of glucuronic acid and its subsequent oxidation. In a small amount is released through the kidneys.
INDICATIONS
- complex treatment of myocardial infarction, coronary heart disease, cardiac arrhythmias caused by the use of cardiac glycosides, against myocardial dystrophy after infectious diseases;
- liver disease (hepatitis, cirrhosis, fatty degeneration);
- operations on an isolated kidney (as a means of pharmacological protection when the circulation is turned off).
DOSING MODE
The drug is used iv in a slow jet or drip (40-60 drops / min). Treatment begins with the introduction of 200 mg (10 ml of a solution of 20 mg / ml) 1 time / day; then, with good tolerability, the dose is increased to 400 mg (20 ml of a solution of 20 mg / ml) 1-2 times / day. Duration of treatment is 10-15 days.
Jet injection of the drug is possible for acute heart rhythm disorders in a single dose of 200-400 mg (10-20 ml of a solution of 20 mg / ml).
For pharmacological protection of the kidneys subjected to ischemia, riboxin is given intravenously in a single dose of 1200 mg (60 ml of a solution of 20 mg / ml) for 5-15 minutes before clotting the renal artery, and then 800 mg (40 ml of a solution of 20 mg / ml) immediately after the restoration of blood circulation.
For intravenous administration, a solution of 20 mg / ml is diluted in a 5% solution of dextrose (glucose) or 0.9% sodium chloride solution (up to 250 ml).
SIDE EFFECT
Allergic reactions: skin itching, skin hyperemia (the drug should be discarded).
Rarely: increased concentration of uric acid in the blood, exacerbation of gout (with prolonged use).
CONTRAINDICATIONS
- gout;
- Hyperuricemia;
- Pregnancy;
- lactation period;
- age under 18 years (effectiveness and safety not established);
- Hypersensitivity to the drug.
With caution: kidney failure.
PREGNANCY AND LACTATION
The drug is contraindicated in pregnancy and lactation.
APPLICATION FOR FUNCTIONS OF THE LIVER
With caution: kidney failure.
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
According to the testimony.
APPLICATION FOR CHILDREN
Contraindicated in children under 18 years.
SPECIAL INSTRUCTIONS
Riboxin is not used for emergency correction of cardiac disorders.
When itching and hyperemia of the skin, treatment with the drug should be discarded.
During prolonged treatment it is desirable to control the concentration of uric acid in the blood and urine.
OVERDOSE
At present, no cases of overdose have been reported.
DRUG INTERACTION
Immunosuppressants reduce the effectiveness of Riboxin.
When combined with cardiac glycosides, the drug can prevent the occurrence of arrhythmias, enhance the positive inotropic effect.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
Store the drug in a dark place at a temperature of 18 В° to 25 В° C. Keep out of the reach of children.
Shelf life - 2 years. Do not use after the expiration date printed on the package.
